Omega Therapeutics, Inc.

Ownership Transactions Reported by 24 Insiders

Symbol
OMGA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
140 First Street, Suite 501, Cambridge, Massachusetts

There are no Buy or Sell transactions made by insiders since 7/8/2023

Omega Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Flagship Pioneering Inc. 10%+ Owner $247 M Feb 27, 2023
Invus Public Equities, L.P. 10%+ Owner $18.2 M Jul 30, 2021
Flagship Pioneering Fund VII General Partner LLC 10%+ Owner $10.6 M Feb 27, 2023
Rudolf Jaenisch 10%+ Owner $6.35 M Jul 29, 2021
David A. Berry Director $425 K Aug 3, 2021
Barbara Y. Chan Chief Accounting Officer $301 K May 31, 2024
Roger Sawhney Chief Financial Officer Mar 9, 2022
Joshua Reed Chief Financial Officer Feb 7, 2024
Elliott Levy Director Jun 20, 2024
Richard A. Young Director Jun 20, 2024
John Mendlein Director Jun 20, 2024
Kevin McManus Chief Human Resources Officer Feb 28, 2023
Rainer Boehm Director Jun 20, 2024
Michelle C. Werner Director Jun 20, 2024
Mary Szela Director Jun 20, 2024
Thomas McCauley Chief Scientific Officer Feb 7, 2024
Mahesh Karande President and CEO, Director Feb 7, 2024
Ling Zeng Chief Legal and Administrative Officer Feb 7, 2024
Yan Moore Chief Medical Officer Feb 7, 2024
Kaan Certel Chief Business Officer May 31, 2024
Richard N. Kender Director Jun 20, 2024
Luke M. Beshar Director Jun 7, 2023
Christian Schade Director Jun 20, 2024
Noubar Afeyan Director, 10%+ Owner Jun 7, 2023

Recent Insider Transactions by Companies or Individuals for Omega Therapeutics, Inc.

Insider Class Transaction % Value $ Price $ Shares Shares Owned Date Ownership